Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors (Q83534480)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

Suzanne G Nodop Mazurek

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Jun Li

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Gerald H Nabozny

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Glenn A Reinhart

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Akalushi C Muthukumarana

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Paul C Harrison

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Ryan M Fryer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

2 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacological and Toxicological Methods

24 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

89-96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

Preclinical and clinical studies of MMP inhibitors in cancer

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

A simple, sensitive, and objective method for early assessment of acrylamide neuropathy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

Clinical potential of matrix metalloprotease inhibitors in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

MMP induction and inhibition in myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

Matrix metalloproteinases: biologic activity and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

Marimastat: the clinical development of a matrix metalloproteinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.02.002

10.1016/J.VASCN.2011.02.002

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21376127%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference